文献速递泌尿生殖腹部MR

前列腺影像质量(PI-QUAL)评分对活检检出临床显著前列腺癌的影响

Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy.
PubMed 文献 · Eur J Radiol · 2023-04-28

该研究纳入300例同时接受多参数MRI和活检的患者,回顾性由两名放射科医生共识评定PI-QUAL评分,并与活检前PI-RADS评分及活检结果相关联。结果显示83%扫描质量最佳(PI-QUAL≥4),17%为次优(PI-QUAL<4);次优质量扫描的阳性预测值较低(35% vs 48%),且PI-RADS 3和4-5的csPCa检出率均较低。结论认为扫描质量可能影响前列腺mpMRI的诊断性能。

要点

  • PI-QUAL<4的扫描阳性预测值较低,报告时需关注图像质量对诊断信心的影响。
  • 次优质量扫描中PI-RADS 3分被转诊活检的比例更高(51% vs 33%)。
  • PI-QUAL<4时PI-RADS 3和4-5的csPCa检出率分别为15%和56%,均低于最佳质量扫描。

局限性

  • 回顾性研究设计
  • PI-QUAL评分由两名放射科医生共识评定,未报告评分者间一致性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the impact of Prostate Imaging Quality (PI-QUAL) scores on the diagnostic performance of multiparametric MRI (mpMRI) in a targeted biopsy cohort.

PATIENTS AND METHODS: 300 patients who underwent both mpMRI and biopsy were included. PI-QUAL scores were retrospectively assigned by two radiologists in consensus and were correlated to pre-biopsy PI-RADS scores and biopsy outcomes. Clinically significant prostate cancer (csPCa) was defined as ISUP grade ≥ 2.

RESULTS: Image quality was optimal (PI-QUAL ≥ 4) in 249/300 (83%) and suboptimal (PI-QUAL < 4) in 51/300 (17%). The proportion of PI-RADS 3 scores referred for biopsy was higher in scans of suboptimal vs optimal quality (51% vs 33%). For PI-QUAL < 4 scans, the positive predictive value (PPV) was lower compared to PI-QUAL ≥ 4 (35% [95%CI: 22, 48] vs 48% [95%CI: 41, 55]; difference -13% [95%CI: -27, 2]; p 0.090), as was the detection rate of csPCa in both PI-RADS 3 and PI-RADS 4-5 (15% vs 23% and 56 vs 63%, respectively). The overall MRI quality increased over time.

CONCLUSIONS: Scan quality may affect the diagnostic performance of prostate mpMRI in patients undergoing MRI-guided biopsy. Scans of suboptimal quality (PI-QUAL < 4) were associated with lower PPV for csPCa.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Brembilla, Lavalle, Parry, et al. Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy. Eur J Radiol. 2023. PMID: 37141845. doi:10.1016/j.ejrad.2023.110849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。